Hypertension, antihypertensive drugs, and erectile dysfunction: An evidence-based perspective;Hipertensión arterial, medicación antihipertensiva y disfunción eréctil: una perspectiva basada en la evidencia

Revista Internacional de Andrologia

Volumn 3, Issue 1, 2005, Pages 13-30

  Mas, M ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Antihypertensive drugs; Erectile dysfunction; Hypertension; Phosphodiesterase 5 inhibitors

Indexed keywords

EID: 34547757215     PISSN: 1698031X     EISSN: 16980409     Source Type: Journal    
DOI: 10.1016/S1698-031X(05)74684-7     Document Type: Review

References (101)

1. Martín Escudero J.C., Simal Blanco F., Carretero Ares J.L., Bellido Casado J., Arzúa Mouronte D., Mena M., et al. Prevalencia, grado de detección, tratamiento y control de la hipertensión arterial en población general. Estudio Hortega. Hipertensión 20 (2003) 148-154
2. Banegas J.R., Rodríguez-Artalejo F., De la Cruz Troca J.J., Guallar-Castillón P., and Del Rey Calero J. Blood pressure in Spain distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension 32 (1998) 998-1002
3. Waier K., Cooper R.S., Banegas J.R., Giampoli S., Hense H.-W., Joffres M., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United Status. JAMA 289 (2003) 2363-2369
4. Banegas Banegas J.R. El problema del control de la hipertensión en España. Hipertensión 19 (2002) 377-381
5. González-Juanatey J.R., Mazón Ramos P., Soria Arcos F., Barrios Alonso V., Rodríguez Radial L., and Bertomeu Martínez V. Actualización (2003) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol 56 (2003) 487-497
6. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The Seventh Report on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC VII Report. JAMA 289 (2003) 2560-2572
7. Williams B., Poulter N.R., Brown M.J., Davis M., McInnes G.T., Potter J.F., et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 328 (2004) 634-640
8. August P. Hypertension in men. J Clin Endocr Metab 84 (1999) 3451-3454
9. Bansal S. Sexual dysfunction in hypertensive men. A critical review of the literature. Hypertension 12 (1988) 1-10
10. Rosen R.C. Alcohol and drug effects on sexual response: human experimental and clinical studies. Annu Rev Sex Res 2 (1991) 119-179
11. Prisant L.M., Carr A.A., Borttini P.B., Solursh D.S., and Solursh L.P. Sexual dysfunction with hypertensive drugs. Arch Intern Med 154 (1994) 730-736
12. Ferrario C.M., and Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens 4 (2002) 424-432
13. Braun M., Wassmer G., Klotz T., Reifenrath B., Mathers M., and Engelmann U. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res 12 (2000) 305-311
14. Martín-Morales A., Sánchez-Cruz J.J., Saenz de Tejada I., Rodríguez- Vela L., Jiménez-Cruz F., and Burgos-Rodríguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina study. J Urol 166 (2001) 569-575
15. Marumo K., Nakashima J., and Murai M. Age-related prevalence of erectile dysfunction in Japan: Assessment by the International Index of Erectile Function. Int J Urol 8 (2001) 53-59
16. Moreira Jr. E.D., Abdo C.H.N., Torres E.B., Lobo C.F.L., and Fittipaldi J.A.S. Prevalence and correlates of erectile dysfunction: results of the Brazilian Study of Sexual Behavior. Urology 58 (2001) 583-588
17. Safarinejad M.R. Prevalence and risk factors for erectile dysfunction in a population-based study in Iran. Int J Imp Res 15 (2003) 246-252
18. Naya Y., Mizutani Y., Ochiai A., Soh J., Kawauchi A., Fujito A., et al. Preliminary report of association of chronic diseases and erectile dysfunction in middle-aged men in Japan. Urology 62 (2003) 532-536
19. Ponholzer A., Temml C., Mock K., Marszalek M., Obermayr R., and Madersbachers S. Prevalence and risk factors for erectile dysfunction in 2,869 men using a validated questionnaire. Eur Urol 47 (2005) 80-85
20. Rosen R.C., Riley A., Wagner G., Osterloch I.H., Kirkpatrick J., and Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49 (1997) 822-830
21. Rosen R.C., Cappelleri J.C., Smith M.D., Lipsky J., and Peña B.M. Development and evaluation of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impotence Res 11 (1999) 319-326
22. Jensen J., Lendorf A., Stimpel H., Ibsen H., and Rosenkilde P. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertension 12 (1999) 271-275
23. Cuéllar de León A.J., Ruiz García M.V., Campos González J.C., Pérez Hoyos S., and Brotons Multo F. Prevalencia de disfunción eréctil en pacientes con hipertensión arterial. Med Clin (Barc) 119 (2002) 521-526
24. Aranda P., Ruilope L.M., Calvo C., Luque M., Coca A., Gil de Miguel A., and Sildenafil Study Group. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish National study. Am J Hypertens 17 (2004) 139-145
25. De Boer B.J., Bots M.I., Lycklama a Nijeholt A.A.B., Moors J.P.C., Pieters H.M., and Verheij Th J.M. Erectile dysfunction in primary care: prevalence and patient characteristics. The ENIGMA study. Int J Imp Res 16 (2004) 356-364
26. Guirao Sánchez L., García-Giralda Ruiz L., Sandoval Martínez C., and Mocciaro Loveccio A. Disfunción eréctil en atención primaria como posible marcador del estado de salud: factores asociados y respuesta al sildenafilo. Aten Primaria 30 (2002) 290-296
27. Walczak M.K., Lokhandwala N., Hodge M.B., and Guay A.T. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 5 (2002) 19-24
28. Seftel A.D., Sun P., and Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 171 (2004) 2341-2345
29. Grimm R.H., Grandin G.A., Prineas R.J., McDonald R.H., Lewis C.E., Flack J.M., et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 29 (1997) 8-14
30. Ruiz Romero J. La disfunción eréctil como marcador del estado de salud y de la calidad de vida: una posibilidad para diseñar una intervención educativa sobre la salud sexual masculina. Rev Int Androl 2 (2004) 43-45
31. Burchardt M., Burchardt T., Anastasiadis A.G., Kiss A.J., Shabsigh A., De la Taille A., et al. Erectile dysfunction is a marker for cardiovascular complications and psychological functioning in men with hypertension. Int J Impot Res 13 (2001) 276-281
32. Finger W.W., Lund M., and Slagle M.A. Medications that may contribute tom sexual disorders. A guide to assessment and treatment in family practice. J Fam Pract 44 (1997) 33-43
33. Meinhardt W., Kropman R.F., Vermeij P., Lycklama a Nijeholt A.A.B., and Zwartendijk J. The influence of medication on erectile function. Int J Impot Res 9 (1997) 17-26
34. Thomas J.A. Pharmacological aspects of erectile dysfunction. Jpn J Pharmacol 89 (2002) 101-112
35. Barsky A.J., Saintflor E., Rogers M.P., and Borns J.F. Nonspecific medication side effects and the nocebo phenomenon. JAMA 287 (2002) 622-627
36. Bulpitt C.J., Dollery C.T., and Carne S. Changes in symptoms of hypertensive patients after referral to hospital clinic. Br Heart J 38 (1976) 121-128
37. Bauer G.E., Baker J., Hunyor S.N., and Marshall P. Side-effects of antihypertensive treatment: a placebo-controlled study. Clin Sci Mol Med 55 (1978) 341s-344s
38. Feldman H.A., Goldstein I., McKinlay J.B., Hatzichristou D.G., and Krane R.J. Impotence and its medical and psychosocial correlates in men aged 40-70: results of the Massachusetts Male Aging Study. J Urol 151 (1994) 54-61
39. Jaffe A., Chen Y., Kisch E.S., Fischel B., Alon M., and Stern N. Erectile dysfunction in hypertensive subjects. Assessment of potential determinants. Hypertension 28 (1996) 859-862
40. Croog S.H., Levine S., Sudilovsky A., Baume R.M., and Clive J. Sexual symptoms in hypertensive patients. A clinical trial of hypertensive medications. Arch Intern Med 148 (1988) 786-794
41. Derby C.A., Barbour M.M., Hume A.L., and McKinlay J.B. Medication use and prevalent erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 21 (2001) 676-683
42. Burchardt M., Burchardt T., Anastasiadis A.G., Baer L., Kiss A.J., Shabsigh A., et al. Hypertension is associated with severe erectile dysfunction. J Urol 164 (2000) 1188-1191
43. Blumentals W.A., Brown R.R., and Gómez-Caminero A. Antihypertensive treatment and erectile dysfunction in a cohort of type II diabetes patients. Int J Impot Res 15 (2003) 314-317
44. Veterans Administation Cooperative Study Group on Antihypertensive Agents. Comparison of propanolol and hydrochlorotiazide for the initial treatment of hypertension. JAMA 248 (1982) 2004-2011
45. Preston R.A., Materson B.J., Reda D.J., and Williams D.W. Placeboassociated blood pressure response and adverse effects in the treatment of hypertension. Arch Int Med 160 (2000) 1449-1454
46. Silvestri A., Galetta P., Cerquetani E., Marazzi G., Patrizi R., Fini M., et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 24 (2003) 1928-1932
47. García del Pozo J., Ramos Sevillano E., De Abajo F.J., and Mateos Campos R. Utilización de antihipertensivos en España (1995-2001). Rev Esp Cardiol 57 (2004) 241-249
48. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Lancet 2 (1981) 539-543
49. Wassertheil-Smoller S., Blaufox D., Oberman A., Davis B.R., Swencionis C., O'Connell Knerr M., et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med 114 (1991) 613-620
50. Chang S.W., Fine R., Siegel D., Chesney M., Black D., and Hulley S.B. The impact of diuretic therapy on reported sexual function. Arch Intern Med 151 (1991) 2402-2408
51. Materson B.J., Reda D.J., Cushman W.C., Massie B.M., Freis E.D., Kochar M.S., et al. Single drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328 (1993) 914-921
52. Cushman W.C., Cohen J.D., Jones R.P., Marbury T.C., Rhoades R.B., et al. Comparison of the fixed combination of enalapril/diltiazem E/R and their monotherapies in stage 1 to 3 essential hypertension. Am J Hypertens 11 (1998) 23-30
53. Fogari R., Zoppi A., Poletti L., Marasi G., Mugellini A., and Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 14 (2001) 27-31
54. Broekman C.P., Haensel S.M., Van de Ven L.L., and Slob A.K. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 18 (1992) 325-331
55. Velasco Martín A., and Serrano Molina J.S. Tratamiento de la hipertensión arterial. In: Velasco Martín A., Alsásua del Valle A., Carvajal García-Pando A., Dueñas Laita A., De la Gala Sánchez F., García Méndez P., et al. (Eds). Farmacología clínica y terapéutica Médica (2004), McGraw-Hill Interamericana, Madrid 235-244
56. Omvik P., Thaulow E., Herland O.B., Eide I., Midha R., and Turner R.R. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. J Hypertens 11 (1993) 103-113
57. Itskovitz H.D. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2,214 clinical practice settings. Clin Ther 16 (1994) 490-504
58. Andersson K.-E. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 170 (2003) S6-S14
59. Fogari R., Preti P., Derosa G., Marasi G., Zoppi A., Rinaldi A., et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterona in hypertensive men. Eur J Clin Pharmacol 58 (2002) 177-180
60. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2 (2003) 29-34
61. Della Chiesa A., Pfiffner D., Meier B., and Hess O.M. Sexual activity in hypertensive men. J Human Hypert 17 (2003) 515-521
62. Llisterri J.L., Lozano Vidal J.V., Aznar Vicente J., et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 321 (2001) 336-341
63. Kifor I., Williams G.H., Vickers M.A., Sullivan M.P., Jodbert P., and Dluhy R.G. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 157 (1997) 1920-1925
64. Becker A.J., Uckert S., Stief C.G., Scheller F., Knaff W.H., Hartmann U., et al. Plasma levels of angiotensin II during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology 58 (2001) 805-810
65. Beto J.A., and Bansal V.K. Quality of life in treatment of hypertension. A metaanalysis of clinical trials. Am J Hypertens 5 (1992) 125-133
66. Prisant L.M., Weir M.R., Frishman W.H., Neutel J.M., Davidov M.E., and Lewin A.J. Self reported sexual dysfunction in men and women treated with bisoprolol, hydrochlorothiazide, enalapril, amlodipine, placebo, or bisoprolol/hydrochlorothiazide. J Clin Hypertens (Greenwich) 1 (1999) 22-26
67. Ko D.T., Hebert P.R., Coffey C.S., Sedrakyan A., Curtis J.P., and Krumholz H.M. β-Blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 288 (2002) 351-357
68. Piha J., and Caja R. Effects of moxonidine and metoprolol in penile circulation in hypertensive men with erectile dysfunction: results of a pilo study. Int J Impot Res 15 (2003) 287-289
69. Solomon H., Man J.W., and Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 89 (2003) 251-254
70. Rajfer J. Endothelial dysfunction as a cause of erectile dysfunction: misdiagnosis or misnomer?. Urology 64 (2004) 193-194
71. Cardillo C., Kilcoyne C.M., Quyyumi A.A., Cannon III R.O., and Panza J.A. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hipertensión. Circulation 97 (1998) 851-856
72. Paniagua O.A., Bryant M.B., and Panza J.A. Role of endothelial nitric oxide in shear stress-induced vasodilation of human microvasculature diminished activity in hypertensive and hypercholesterolemic patients. Circulation 103 (2001) 1752-1758
73. Kaiser D.R., Billups K., Mason C., Wetterling R., Lundberg J.L., and Bank A.J. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 43 (2004) 179-184
74. Behr-Roussel D., Gorny D., Mevel K., Compagnie S., Kern P., Sivan V., et al. Erectile dysfunction: an early marker for hypertension? A longitudinal study in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 288 (2005) R276-R283
75. Ushiyama M., Morita T., Kuramochi T., Yagi S., and Katayama S. Erectile dysfunction in hypertensive rats results from impairment of the relaxation evoked by neurogenic carbon monoxide and nitric oxide. Hypertens Res 27 (2004) 253-261
76. Toblli J.E., Stella I., Inserra F., Ferder L., Zeller F., and Mazza O.N. Morphological changes in cavernous tissue in spontaneously hypertensive rats. Am J Hypertens 13 (2000) 686-692
77. Hale T.M., Okabe H., Heaton J.P., and Adams M.A. Antihypertensive drugs induce structural remodeling of the penile vasculature. J Urol 166 (2001) 739-745
78. Dorrance A.M., Lewis R.W., and Mills T.M. Captopril treatment reverses erectile dysfunction in male stroke prone spontaneously hypertensive rats. Int J Impot Res 14 (2002) 494-497
79. Toblli J.E., Stella I., Mazza O.N., Ferder L., and Inserra F. Different effect of losartan and amlodipine on penile structures in male spontaneously hypertensive rats. Am J Nephrol 24 (2004) 614-623
80. Toblli J.E., Stella I., Mazza O.N., Ferder L., and Inserra F. Candesartan cilexetil protects cavernous tissue in spontaneously hypertensive rats. Int J Impot Res 16 (2004) 305-312
81. Toblli J.E., Stella I., Mazza O.N., Ferder L., and Inserra F. Protection of cavernous tissue in male spontaneously hypertensive rats beyond blood pressure control. Am J Hypertens 17 (2004) 516-522
82. Schiffrin E.L., Park J.B., Intengan H.D., and Touyz R.M. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 101 (2000) 1653-1659
83. Millar R.A. Propanolol and impotente. Ann Int Med 85 (1976) 682-683
84. Palou Redorta J., Morote Robles J., Costa Pagés J., and Arnau de Bolós J.M. Impotencia coeundi por hidroclorotiazida. Med Clin (Barc) 86 (1986) 175-176
85. Pertusa S., Bueno J.M., and Quince F. Impotencia sexual por nifedipino. Med Clin (Barc) 98 (1992) 78
86. Gresser U., and Gleiter O.H. Erectile dysfunction: comparison of efficacy and side effects of the PDE5 inhibitors sildenafil, vardenafil and tadalafil. Eur J Med Res 7 (2002) 435-446
87. Kloner R.A., Brown M., Prisant L.M., and Collins M. Sildenafil Study Group. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 14 (2001) 70-73
88. Guay A.T., Pérez J.B., Jacobson J., and Newton R.A. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 22 (2001) 793-797
89. Olsson A.M., Persson C.A., and Swedish Sildenafil Investigators Group. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract 55 (2001) 171-176
90. Martínez Jabaloyas J.M., Gil Salom M., Pastor Hernández F., Villamón Fort R., and García Sisamón F. Eficacia y seguridad del sildenafilo en pacientes con disfunción eréctil e hipertensión arterial. Factores pronósticos de respuesta. Med Clin (Barc) 119 (2002) 281-285
91. Kloner R.A. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 110 (2004) 3149-3155
92. Jackson G., Benjamín N., Jackson N., and Allen M.J. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol B3 (1999) 13C-20C
93. Zusman R.M., Prisant L.M., and Brown M.J. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile function taking concomitant antihypertensive medications. Sildenafil Study Group. J Hypertens 18 (2000) 1965-1969
94. Stanopoulos I., Hatzichristou D., Tryfon S., Tzortzis V.F., Apostolidis A., and Argyropoulou P. Effects of sildenafil on cardiopulmonary responses during stress. J Urol 169 (2003) 1417-1421
95. Kloner R.A., Mitchell M., and Emmick J.T. Cardiovascular effects of tadalafil. Am J Cardiol 92 Suppl (2003) M37-M46
96. Kloner R.A., Mitchell M., and Emmick J.T. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 92 Suppl (2003) M47-M57
97. Kloner R.A., Mohan P., Segerson T., Thibonnier M., Norenberg C., and Padma-Nahan H. Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post hoc analysis of five placebo-controlled trials. J Am Coll Cardiol 41 Suppl A (2003) A276-A277
98. Kloner R.A., Jackson G., Emmick J.T., Mitchell M.I., Bedding A., Warner M.R., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 α-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 172 (2004) 1935-1940
99. Toda N. Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Therap 100 (2003) 215-234
100. Fagan T.C., Buttler S., Marbury., Taylor T.A., Edmonds A., and S.L. APO Study Group. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Am J Cardiol 88 (2001) 760-766
101. Burchardt M., Burchardt T., Anastasiadis A.G., Kiss A.J., Baer L., Pawar R.V., et al. Sexual dysfunction is common and overlooked in female patients with hypertension. J Sex Marital Ther 28 (2002) 17-26